Disclosed herein are embodiments of a compound that can be used as a supramolecular sensor for determining the presence of analytes (e.g., illicit drugs), and for identifying and/or quantifying the analytes. Also disclosed herein is a parallel synthesis method for making compound embodiments, as well as method embodiments for using the compound embodiments. Array embodiments comprising one or more compound embodiments disclosed herein also are described.

A new azo-type quaternary pyridinium salt (Azo-QPS) shows enhanced activity at acidic conditions (e.g., pH=5); in neutral or basic conditions, this new Azo-QPS shows a much lower level (2-50 times less) anti-bacterial activity. The use of such a stimulus-enhance antibiotic can response to the proliferation of bacteria directly. It helps reduce or prevent the build-up of potent antibacterial agents in the oral environment. The antibacterial properties of Azo-QPS are activated when the environmental pH becomes acidic; this acidic pH may be indicative of the accumulation of Streptococcus mutans, or the initiation of tooth decay.

A new azo-type quaternary pyridinium salt (Azo-QPS) shows enhanced activity at acidic conditions (e.g., pH=5); in neutral or basic conditions, this new Azo-QPS shows a much lower level (2-50 times less) anti-bacterial activity. The use of such a stimulus-enhance antibiotic can response to the proliferation of bacteria directly. It helps reduce or prevent the build-up of potent antibacterial agents in the oral environment. The antibacterial properties of Azo-QPS are activated when the environmental pH becomes acidic; this acidic pH may be indicative of the accumulation of Streptococcus mutans, or the initiation of tooth decay.

The present invention relates to the use of one or more particular pyridinium salts for the treatment of keratin substances, particularly human keratin fibres such as hair. The invention also relates to a method for the treatment of keratin substances using said salts and optionally one or more chemical oxidizing agents. The invention also relates to a composition for lightening keratin substances comprising one or more pyridinium salts as defined hereinafter and one or more chemical oxidizing agents. The present invention also relates to one or more particular pyridinium salts and also to compositions containing them, especially compositions comprising a physiologically acceptable medium.

The present invention relates to the use of one or more particular pyridinium salts for the treatment of keratin substances, particularly human keratin fibres such as hair. The invention also relates to a method for the treatment of keratin substances using said salts and optionally one or more chemical oxidizing agents. The invention also relates to a composition for lightening keratin substances comprising one or more pyridinium salts as defined hereinafter and one or more chemical oxidizing agents. The present invention also relates to one or more particular pyridinium salts and also to compositions containing them, especially compositions comprising a physiologically acceptable medium.

Newly synthesized derivatives of BAS00127538 have been discovered to possess antibiotic activity and to combat resistant bacterial strains. Compounds and pharmaceutical compositions containing these compounds are described, and are based on a generic scaffold structure. Synthetic methods and methods of using the compounds also are described. Preferred compounds bind to Lipid II with high affinity, have markedly reduced cytotoxicity compared to BAS00127538, and retain activity against drug-resistant strains of Enterococci. They are stable in plasma, have dramatically improved pharmacokinetic and pharmacodynamics properties, and possess in vivo efficacy in a mouse model of sepsis.

##STR00001##

The present invention relates to modulators of ATP-Binding Cassette (ABC) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

The present invention relates to modulators of ATP-Binding Cassette (ABC) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

Described herein are oxime compounds capable of inactivating a nerve agent, blood brain barrier (BBB)-penetration, and/or reactivation of nerve agent-inhibited acetylcholinesterase (AChE) and related methods, systems and compositions for inactivation of one or more nerve agents, therapeutic and/or prophylactic treatment of an individual, and/or decomposition of nerve agent for decontamination.

Described herein are oxime compounds capable of inactivating a nerve agent, blood brain barrier (BBB)-penetration, and/or reactivation of nerve agent-inhibited acetylcholinesterase (AChE) and related methods, systems and compositions for inactivation of one or more nerve agents, therapeutic and/or prophylactic treatment of an individual, and/or decomposition of nerve agent for decontamination.